Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

515
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
515
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

1.8K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.8K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

829
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
829
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

754
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
754
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

667
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
667
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

328
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbidopa/levodopa products may induce vitamin B6 deficiency and seizures.

The American journal of nursing·2026
Same author

True generic of Flovent HFA inhaler now approved.

The American journal of nursing·2026
Same author

Second drug approved for achondroplasia.

The American journal of nursing·2026
Same author

Updates from the FDA on GLP-1 agonists.

The American journal of nursing·2026
Same author

More warnings about over-the-counter supplements containing hidden drugs.

The American journal of nursing·2026
Same author

Drug for iron deficiency is now approved for pediatric patients.

The American journal of nursing·2026

Related Experiment Video

Updated: Nov 16, 2025

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test
07:54

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test

Published on: June 29, 2018

13.9K

Stronger Boxed Warning for Benzodiazepines.

Diane S Aschenbrenner1

  • 1Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch : daschenbrenner@ndm.edu .

The American Journal of Nursing
|February 24, 2021
PubMed
Summary

Benzodiazepine medications now carry a stronger warning about overdose risks, particularly when mixed with other substances. This update highlights dangers including addiction, dependence, and withdrawal symptoms associated with these widely prescribed drugs.

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

592
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.9K

Related Experiment Videos

Last Updated: Nov 16, 2025

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test
07:54

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test

Published on: June 29, 2018

13.9K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

592
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.9K

Area of Science:

  • Pharmacology
  • Public Health
  • Drug Safety

Background:

  • Benzodiazepines are commonly prescribed medications with a known risk profile.
  • Previous warnings have not fully conveyed the severity of potential harms.
  • Concurrent use with other central nervous system depressants increases risks.

Purpose of the Study:

  • To communicate the updated and strengthened boxed warning for benzodiazepine medications.
  • To inform healthcare providers and patients about increased risks associated with benzodiazepine use.
  • To emphasize the critical dangers of combining benzodiazepines with opioids, alcohol, or illicit substances.

Main Methods:

  • Review and analysis of post-marketing safety data.
  • Evaluation of overdose and mortality trends associated with benzodiazepine use.
  • Assessment of abuse, misuse, addiction, dependence, and withdrawal patterns.

Main Results:

  • The boxed warning has been strengthened to underscore overdose and death risks.
  • Significant emphasis is placed on the dangers of co-administration with opioids, alcohol, and illicit drugs.
  • Increased recognition of the potential for abuse, misuse, addiction, physical dependence, and withdrawal.

Conclusions:

  • The updated boxed warning necessitates heightened vigilance regarding benzodiazepine prescribing and patient monitoring.
  • Healthcare professionals must counsel patients on the severe risks, especially when combined with other substances.
  • This strengthened warning aims to mitigate adverse events and improve patient safety outcomes.